Healthcare Management Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory… AIT News Desk Jun 11, 2022 Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX® (daratumumab) subcutaneous (SC) formulation improved clinical…
Healthcare Management Janssen Submits Biologics License Application To U.S. FDA Seeking Approval Of Teclistamab For The… AIT News Desk Dec 29, 2021 The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and…